San Francisco Bay Area
Dr. Shidong Jia is an internationally recognized leader in precision medicine and a pioneer in next-generation liquid biopsy technologies. He has authored more than 50 peer-reviewed publications spanning blood-, urine- and CSF-based liquid biopsy studies across multiple cancer types. As Founder and CEO of Predicine, headquartered in Silicon Valley, Dr. Jia has led the development of advanced liquid biopsy platforms leveraging cell-free DNA and RNA to enable minimally invasive molecular diagnostics. These technologies support treatment selection, therapy monitoring, minimal residual disease (MRD) detection, and early cancer detection. Notably, Predicine's pioneering technologies and assay platforms have been utilized in high-impact publications in NEJM and Nature Medicine by leading organization, including Roche/Genentech, and have been presented at major international conferences. Predicine's flagship liquid biopsy assay, PredicineCARE, has received FDA Breakthrough Device Designation, New York State approval, and is currently being advanced as a companion diagnostic (CDx) in collaboration with leading pharmaceutical companies including Johnson & Johnson. Dr. Jia founded Predicine in 2015 to address a critical unmet need he encountered firsthand while serving as a biomarker team lead at Genentech, where he supported the clinical development of Ipatasertib (AKT inhibitor). Through this program, he recognized that existing liquid biopsy solutions used in clinical trials lacked the accuracy, accessibility, and affordability required for robust biomarker-driven clinical drug development. Driven by a passion to accelerate clinical trials, Dr. Jia transitioned from a user to a developer by leaving Genentech and establishing Predicine with a clear commitment to developing Accurate, Accessible, and Affordable (AAA) liquid biopsy solutions purpose-built for global clinical trials, CDx development and patient testing. Predicine operates laboratories and teams in Hayward (CA), Houston (TX), Chicago (IL), and Shanghai (China), delivering AI-empowered, harmonized liquid biopsy testing solutions for MNC biopharma partners and patients worldwide. Today, Dr. Jia continues to drive innovation in AI-empowered liquid biopsy technologies and their clinical applications, with a focus on advancing global clinical drug development and improving patient care through AAA molecular diagnostics. Predicine's mission is to bring the best hospitals to every community and bring the best doctor to every home.
Vision: Bringing the best hospital to every community, the best doctor to every home. Mission: Empowering the global healthcare ecosystem through innovation. Predicine is a global molecular insights company committed to advancing precision medicine in oncology and infectious diseases. With proprietary cell-free DNA- and RNA-based liquid biopsy technologies, Predicine enables minimally invasive solutions for treatment selection, therapy monitoring, minimal residual disease (MRD) assessment, and early cancer detection. The company's portfolio includes innovative blood-, urine-, and tissue-based molecular diagnostic assays. Among them is PredicineCARE, a groundbreaking ctDNA test that has achieved: - FDA Breakthrough Device Designation (BDD) - New York State Department of Health Approval - Companion Diagnostic (CDx) collaboration with pharma companies including Janssen (Johnson & Johnson) Predicine’s cutting-edge technology has been integral to global clinical trials by top pharmaceutical companies, with results featured in: - NEJM (2025) by Roche - NEJM (2024) by Roche - NEJM (2023) by Genentech - Nature Medicine (2023) by Genentech - Nature Medicine (2024) by Incyte - Annals of Oncology (2024) by BMS Predicine provides harmonized biomarker testing solutions in its CLIA- and CAP-certified laboratory network in the U.S. (Silicon Valley, Chicago, Houston) and China (Shanghai). By partnering with biopharma companies, academic institutions, and hospitals, Predicine supports clinical trials, CDx development and global commercialization across the U.S., Europe, Japan, China, and beyond. To learn more, visit www.predicine.com. Predicine — Care for Life!
As Editor-in-Chief of the Journal of Circulating Biomarkers, a journal I had the privilege of naming, I played a pivotal role in shaping its mission and scope. The journal is dedicated to advancing the international dialogue on the translational study of exosomes, microvesicles, circulating tumor cells, cell-free circulating DNA, and circulating protein and lipid markers in the context of precision medicine and clinical drug development. My primary responsibilities included: - Defining the strategic vision and scope of the journal to bridge basic science with translational and clinical applications, fostering impactful contributions to the field. - Building an international scientific community by engaging experts and thought leaders to support cutting-edge research and technology development in circulating biomarkers. The Journal of Circulating Biomarkers continues to serve as a vital platform for disseminating breakthroughs in this rapidly evolving field. For more information, visit: Journal of Circulating Biomarkers.
1 - Program Lead: Directed cross-functional biomarker team efforts, spearheading drug and companion diagnostic co-development for the oncology pipeline. This role encompassed early and late-stage research, early clinical development, and Phase I/II clinical trials. A key achievement was leading the AKT (Ipatasertib) program through the Lifecycle Investment Point (LIP) milestone, advancing its Phase II clinical trial into Phase III pivotal development. 2 - Disease Lead: Developed and executed prostate cancer biomarker strategies to support global oncology clinical trials, ensuring alignment with precision medicine goals and enhancing therapeutic impact. 3 - Lab Head & Principal Investigator: Managed an R&D laboratory focused on translational research, cutting-edge technology development, and the implementation of precision medicine approaches. This work facilitated the discovery and integration of biomarkers into clinical trials, bridging science with impactful patient care. For more information about Genentech’s work, visit: www.gene.com.
Investigating the mechanisms of drug resistance to Ribociclib (LEE011), an oral small-molecule inhibitor of CDK4/6, to inform and support the development and optimization of future therapeutic strategies. Ribociclib later received FDA approval as a first-line treatment for HR+/HER2- advanced breast cancer, underscoring its transformative impact on patient care. For more information about Novartis' innovative research, visit: www.nibr.com.